vimarsana.com

Page 2 - Williamg Wierda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves Pirtobrutinib for Previously Treated CLL/SLL

The FDA has granted an accelerated approval to pirtobrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

FDA Grants Accelerated Approval to Pirtobrutinib for Patients With CLL/SLL After Use of BTK, BCL-2 Inhibitors

Jaypirca® (pirtobrutinib) Now Approved by U S FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.